, Volume 15, Issue 6, pp 347-352
Date: 17 Aug 2012

Correlation of Activated STAT3 Expression with Clinicopathologic Features in Lung Adenocarcinoma and Squamous Cell Carcinoma

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Background and Objective: Signal transducer and activator of transcription (STAT) 3, a member of the STAT family of transcription factors in the Janus kinase (JAK)/STAT signaling pathway, is involved in cell proliferation and apoptosis. STAT3 is activated through phosphorylation (p-STAT3) and is highly expressed in many malignancies. The aims of the present study were to evaluate STAT3 activation (p-STAT3 protein levels) in lung adenocarcinoma and squamous cell carcinoma, and to investigate its correlation with clinicopathologic features of these malignancies.

Methods: Expression of p-STAT3 was detected by immunohistochemistry in tissue from 127 lung carcinomas (100 adenocarcinomas and 27 squamous cell carcinomas) and 56 normal lungs. Genomic DNA was extracted from frozen patient tissue samples, and key epidermal growth factor receptor (EGFR) mutation sites in exons 18 through 21 of the EGFR gene were amplified and sequenced.

Results: On the basis of the intensity and percentage of p-STAT3 immunoreactivity, samples were divided into negative and positive p-STAT3 expression groups. 103 of these 183 samples (56.3%) showed immunoreactivity for p-STAT3, and this frequency was significantly increased in carcinoma tissue compared with normal tissue (p = 0.001). Positive p-STAT3 expression was detected in 82 of the 127 carcinomas (64.6%) but in only 21 of the 56 normal tissue samples (37.5%). Among the 127 cases of non-small cell lung cancer, p-STAT3 immunoreactivity was significantly correlated with sex (p = 0.004), smoking history (p = 0.006), EGFR mutation status (p = 0.003), clinical stage (p = 0.034), and lymph node metastasis (p = 0.009).

Conclusion: Our results suggest that p-STAT3 is an important factor during carcinogenesis and metastasis of lung carcinoma, and its relationship to EGFR mutation status may provide potential targeting opportunities in future therapies.